S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company

Oxford Biomedica Share Price, News & Analysis (LON:OXB)

GBX 198.40
+16.20 (+8.89%)
(As of 12/8/2023 ET)
Compare
Today's Range
180.73
▼
200.50
50-Day Range
166.60
▼
307.50
52-Week Range
164.29
▼
575
Volume
628,402 shs
Average Volume
175,346 shs
Market Capitalization
£192.01 million
P/E Ratio
N/A
Dividend Yield
4.57%
Price Target
GBX 605
Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades

Oxford Biomedica MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
204.9% Upside
GBX 605 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.60mentions of Oxford Biomedica in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
£12.12 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

See Top Rated MarketRank™ Stocks Here

OXB stock logo

About Oxford Biomedica Stock (LON:OXB)

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

OXB Stock Price History

OXB Stock News Headlines

December 5, 2023 | americanbankingnews.com
Oxford Biomedica (LON:OXB) Shares Pass Below Two Hundred Day Moving Average of $335.58
December 4, 2023 | msn.com
Oxford Biomedica inks deal to provide ‘footprint’ in EU market
December 9, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
December 4, 2023 | finance.yahoo.com
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
October 22, 2023 | finance.yahoo.com
Oxford Biomedica's UK£39m Market Cap Fall Books Insider Losses
September 22, 2023 | finance.yahoo.com
Oxford Biomedica First Half 2023 Earnings: Misses Expectations
September 20, 2023 | finance.yahoo.com
Oxford BioMedica shares soar as vaccine maker raises earnings guidance
July 18, 2023 | finance.yahoo.com
Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook
December 9, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
May 25, 2023 | msn.com
RBC Capital Markets Reiterates Oxford Biomedica (LSE:OXB) Outperform Recommendation
May 15, 2023 | finance.yahoo.com
Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
May 5, 2023 | finance.yahoo.com
Why Investors Shouldn't Be Surprised By Oxford Biomedica plc's (LON:OXB) Low P/S
April 26, 2023 | finance.yahoo.com
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
April 25, 2023 | markets.businessinsider.com
Oxford Biomedica Posts FY Loss
April 21, 2023 | marketwatch.com
2023-2030 "CGT CDMO Market" Share | Global Industry Analysis and Forecast
April 12, 2023 | marketwatch.com
2023-2030 Global CGT CDMO Market is Growing Rapidly with Modern Trend
March 26, 2023 | marketwatch.com
CGT CDMO Market Share and Forecast till 2030
March 15, 2023 | benzinga.com
Oxford BioMedica Stock (OTC:OXBDF), Quotes and News Summary
March 11, 2023 | finance.yahoo.com
As Oxford Biomedica plc's market cap (LON:OXB) drops to UK£484m, insiders might be questioning their decision to buy earlier this year
February 25, 2023 | marketwatch.com
What is a CAGR of CGT CDMO Market? CGT CDMO Market Value in 2028 with Competition Analysis Data of Top Key Players
February 22, 2023 | marketwatch.com
CGT CDMO Market Size Global Research Report, 2023 - 2028
January 30, 2023 | marketwatch.com
CGT CDMO Market Size 2023 Trend and Opportunities, Analysis, CAGR and Value Chain Study, Business Growth to 2028
January 20, 2023 | marketwatch.com
CGT CDMO Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028
January 12, 2023 | marketwatch.com
CGT CDMO Market Present Development Scenario and Growth Prospects to help you understand the Implications for Your Business | Newest 112 Insights
January 1, 2023 | finance.yahoo.com
A Look At The Intrinsic Value Of Oxford Biomedica plc (LON:OXB)
December 14, 2022 | yahoo.com
Oxford Biomedica Solutions forms new partnerships with three biotechnology companies
December 9, 2022 | marketwatch.com
CGT CDMO Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028
See More Headlines
Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:OXB
CUSIP
N/A
CIK
N/A
Web
www.oxfordbiomedica.co.uk
Phone
+44-1865-783000
Fax
N/A
Employees
891
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 605
High Stock Price Target
GBX 1,010
Low Stock Price Target
GBX 310
Potential Upside/Downside
+204.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-61,630,000.00
Net Margins
-51.78%
Pretax Margin
N/A
Return on Equity
-30.64%
Return on Assets
-12.05%

Debt

Debt-to-Equity Ratio
57.10
Current Ratio
3.32
Quick Ratio
1.67

Sales & Book Value

Annual Sales
£119.02 million
Price / Sales
1.61
Cash Flow
GBX 65.99 per share
Price / Cash Flow
3.01
Book Value
GBX 178 per share
Price / Book
1.11

Miscellaneous

Outstanding Shares
96,780,000
Free Float
N/A
Market Cap
£192.01 million
Optionable
Not Optionable
Beta
1.02
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Stuart Paynter (Age 50)
    CFO, Company Secretary & Director
    Comp: $832k
  • Dr. Frank Mathias (Age 61)
    CEO & Director
  • Mr. Thierry Cournez
    COO & Site Head of UK Operations
  • Dr. James Miskin Ph.D.
    Chief Technical Officer
  • Dr. Kyriacos Mitrophanous Ph.D.
    Chief Scientific Officer
  • Mr. Matthew Treagus
    Chief Information Officer & Chief of Staff
  • Sophia Bolhassan
    Head of Investor Relations
  • Ms. Natalie Louise Walter
    General Counsel
  • Ms. Lisa James
    Chief People Officer
  • Ms. Kati Hudson
    Head of Intellectual Property and Contracts

Key Competitors

View All Competitors

Insiders

View All Insider Transactions














OXB Stock Analysis - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares.
View OXB analyst ratings or view top-rated stocks.

What is Oxford Biomedica's stock price target for 2024?

3 brokers have issued 1-year target prices for Oxford Biomedica's shares. Their OXB share price targets range from GBX 310 to GBX 1,010. On average, they anticipate the company's stock price to reach GBX 605 in the next year. This suggests a possible upside of 204.9% from the stock's current price.
View analysts price targets for OXB or view top-rated stocks among Wall Street analysts.

How have OXB shares performed in 2023?

Oxford Biomedica's stock was trading at GBX 442.50 on January 1st, 2023. Since then, OXB stock has decreased by 55.2% and is now trading at GBX 198.40.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:OXB) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -